The following is a summary of the Paysign, Inc. (PAYS) Q2 2024 Earnings Call Transcript:

Financial Performance:

• Paysign reported a Q2 2024 revenue of $14.3 million, a 29.8% increase year-over-year.

• Adjusted EBITDA rose significantly to $2.24 million, reflecting a 96% increase, translating to $0.04 per fully diluted share.

• Net income for the quarter was reported at $697,000, or $0.01 per fully diluted share.

Business Progress:

• The patient affordability segment experienced a 267% increase in revenue, driving significant margin expansion and contributing to 59% of total revenue growth.

• Paysign added eight new patient affordability programs in Q2, growing the total to 61 active programs.

• Eight new plasma centers were added, reaching a total of 477 centers, with plans to add 5-10 more by year-end.

Opportunities:

• Paysign's growth is driven by its expanding patient affordability and plasma donor compensation businesses.

• The company plans to continue capitalizing on opportunities through robust sales pipelines and strategic expansion into new markets.

Risks:

• The business depends significantly on the performance of its patient affordability programs and plasma donation centers.

More details: PaySign IR

Tips: This article is generated by AI. The accuracy of the content can not be fully guaranteed. For more comprehensive details, please refer to the IR website. The article is only for investors' reference without any guidance or recommendation suggestions.